Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

BOSTON, MA—Tirzepatide improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, no matter how much excess body weight they have, according to an analysis ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

If you continue to have this issue please contact [email protected]. Adults receiving tirzepatide in the SURPASS trials had significant decreases in urine albumin-to-creatinine ratio.

The study's primary endpoint was to evaluate the efficacy of bremelanotide combined with tirzepatide in reducing body weight. Data from this trial are expected later this quarter. The results from ...

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...